this is the fourth blood-based colon cancer screening test that has come along. So far, all have been flops and I fully expect this one will as well.
It's simply not possible to obtain enough mutated DNA from colon cells via the blood stream. If it were possible, Conroy's Invader technology would probably be the best situated - i.e. EXAS already has a leg up on everyone else when the technology finally gets to a point where blood based tests can detect incredibly small amounts of mutant DNA against a huge background of normal DNA.
And some food for thought on using inflammation markers - Aspen Biopharma has been trying to using a panel of "inflammation markers" for their appendicitis test for years. This is a setting that would seem ideal for inflammation markers, but even Aspen is getting piss poor results. Inflammation is just way too of a generic marker family.
We're on the same page. Lots of people have been looking at the problem for years, the best they seem to do is about match a good FIT test (for much higher cost). Whenever a new one comes along, I always take a look, but it always turns out the same way. The exaggerated claims wilt under scrutiny. EXAS is the real deal.
The Sig D guys seem pretty good at algorithms, but no algorithm can extract information that's not there. As KC said, the fundamental limitation for blood tests is biology, not technology.